LIXT — LIXTE BIOTECHNOLOGY HOLDINGS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1335105 ·
Last close
$5.65
Market Cap
$69.96M
52W High
$6.11
52W Low
$2.36
ADV30
71,249
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,987,407 | -1,923,676 | 10,865,298 | 3,250,650 | 1,686,706 |
| Dec 2025 | 0 | — | -1,824,518 | -2,543,894 | 12,733,621 | 5,106,872 | 1,772,070 |
| Sep 2025 | 0 | — | -1,801,354 | -1,980,398 | 5,433,676 | 2,887,874 | 521,422 |
| Jun 2025 | 0 | — | -774,809 | -775,673 | 1,188,578 | 887,212 | 537,122 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,070,618
Investing CF
$-535,102
Financing CF
$10,311,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-58,077,213
Inventory
—
Receivables
—
ST Investments
$2,454,473
EBIT TTM
$-6,000,362
Pretax Income TTM
$-6,009,520
Interest Exp TTM
$9,158
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,107,621 | -6,009,520 | 12,733,621 | 1,772,070 | — | -3,070,618 |
| Dec 2024 | 0 | -3,572,789 | -3,585,965 | 1,145,503 | 318,284 | — | -3,164,536 |
| Dec 2023 | 0 | -5,090,236 | -5,087,029 | 4,308,620 | 313,858 | — | -4,293,265 |
| Dec 2022 | 0 | -6,311,481 | -6,312,535 | 5,560,983 | 395,756 | — | -4,611,737 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | $71.48M | $1.67 | — |
| FLNA | FILANA THERAPEUTICS, INC. | $68.11M | $1.41 | — |
| RFL | Rafael Holdings, Inc. | $67.62M | $1.32 | — |
| MNOV | MEDICINOVA INC | $67.43M | $1.37 | — |
| XBIT | XBiotech Inc. | $73.17M | $2.40 | — |
News headlines (Yahoo Finance, 1h cache)
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
2026-05-14 21:18 · Yahoo
LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment
2026-04-27 18:14 · Yahoo
LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape
2026-04-20 19:00 · Yahoo
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built
2026-04-17 19:30 · Yahoo
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
2026-04-13 19:30 · Yahoo
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
2026-04-13 12:00 · Yahoo
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships
2026-04-10 19:00 · Yahoo
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year
2026-04-02 18:30 · Yahoo
LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
2026-04-01 18:30 · Yahoo
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
2026-03-31 19:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.